Skip to content

Xiclofen: US FDA label indications

US FDA labelNot medical advice

Label details

Brand name
Xiclofen
Generic name
Diclofenac Sodium, Methyl Salicylate
Manufacturer
ASCLEMED USA INC.
Route
Cutaneous
Product type
Human Prescription Drug
Substance
Diclofenac Sodium

Indications and usage (label excerpt)

1. ​INDICATIONS & USAGE Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more.

Warnings (label excerpt)

5. WARNINGS, PRECAUTIONS & ADVERSE REACTIONS 5.1 Risk of Serious Cardiovascular and Gastrointestinal Events Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs, including diclofenac, can lead to new onset of hypertension, or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Avoid the use of diclofenac sodium external in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If diclofenac sodium external is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Avoid using NSAID…

Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).

Trials whose interventions mention this drug

Canadian trials first. A match on the drug name does not mean the trial studied this specific product.

4 trials, recruiting first
PhaseCountries
The Incidence of Thoracic Disc Herniation in Patients Presenting With Chronic Upper Back Pain
NCT05313997
CompletedTurkey (Türkiye)Kocaeli University2022-05-24
Bonipar for Acute and Chronic Musculoskeletal Pain
NCT03471507
CompletedPhase 2United StatesWinston Parris, MD2020-12-15
Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment
NCT03362216
CompletedNot applicablePeking University People's Hospital2009-04-07
Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia
NCT05829707
CompletedPhase 4Osijek University Hospital2009-01-05

Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.